전체 프로그램

ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved95 programs
ADCCurated CoreFDAstaleGenmabApproved

Tisotumab Vedotin (Tisotumab Vedotin)

Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung · Solid Malignancies

#SolidMalignancies#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 14Status Approved
CGTStandard DatabasestaleIovance Biotherapeutics, Inc.Phase 2

TCR (E7 T Cell Receptor, E7 T Cell Receptor (TCR))

Uterine Cervical Neoplasms · Squamous Lntraepithelial Lesions of Vulv

#SquamousLntraepithelialLesionsof#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 124Status Discontinued
AntibodyCurated CorestaleRegeneronPhase 2

Cemiplimab (Cemiplimab)

Breast Neoplasms; Breast Cancer · Solid Tumor

#SolidTumor#Antibody#Phase2#BioJungboMoa-pick#Popular+5
Trials 123Status Recruiting
AntibodyLimited DatastaleElevation OncologyPhase 1

CYRAMZA® (Ramucirumab, Ramucirumab (CYRAMZA®))

Stomach Neoplasm; Gastrointestinal Neoplasms · Stomach Neoplasm

#StomachNeoplasm#Antibody#Phase1#Popular#monoclonal-antibody+3
Trials 84Status Discontinued
CGTStandard DatabasestaleImcyse SAPhase 2

Multi-epitope (ME, Multi-epitope, Multi-epitope (ME) T-cell Receptor Alternate Reading Frame Protein (TARP) vaccine)

Prostatic Neoplasms; Neoplasms of Prostate · FRα

#FR#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 62Status Active
CGTStandard DatabasestaleNational Cancer Institute (NCI)Phase 2

Multi-epitope (ME, Multi-epitope, Multi-epitope (ME) T-cell receptor g alternate reading frame protein (TARP) vaccine)

Prostatic Neoplasms; Prostate Cancer · FRα

#FR#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 61Status Discontinued
AntibodyCurated CorestaleGlaxoSmithKlinePhase 2

Dostarlimab (Dostarlimab)

Neoplasms · Stomach Neoplasm

#StomachNeoplasm#Antibody#Phase2#BioJungboMoa-pick#Popular+3
Trials 60Status Discontinued
CGTLimited DatastaleBinhui Biopharmaceutical Co., L…Phase 1

IDOV-SAFETM (Oncolytic Virus injection, Oncolytic Virus injection(IDOV-SAFETM))

Neoplasms · Neoplasms

#Neoplasms#CGT#Phase1#Popular#cell-gene-therapy+4
Trials 59Status Recruiting
AntibodyLimited DatastaleRochePhase 2

trastuzumab (Herceptin, Pertuzumab and Trastuzumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#Popular#monoclonal-antibody+3
Trials 58Status Recruiting
CGTStandard DatabasestaleCelldex TherapeuticsPhase 2

TCR-transduced T cells (TCR-transduced T cells)

Stage IV Skin Melanoma; Eye; Melanoma · Malignant Epithelial Neoplasms

#MalignantEpithelialNeoplasms#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 51Status Recruiting
AntibodyLimited DatastaleXuekui LiuPhase 2

Zimberelimab (Zimberelimab)

Hend and Neck Squamous Cell Carcinoma Locally Advanced Operable · Prostatic Neoplasms, Castration-Resistan

#ProstaticNeoplasmsCastration-Res#Antibody#Phase2#Popular#monoclonal-antibody+2
Trials 50Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 1

B7-H3-CAR T Cells (B7-H3-CAR T Cells)

Central Nervous System Neoplasms; Atypical Teratoid/Rhabdoid Tumor · B7-H3

#B7-H3#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 35Status Recruiting
AntibodyLimited DatastaleRochePhase 3

atezolizumab (Tecentriq, Tiragolumab and Atezolizumab)

Head and Neck Neoplasms; MSI-H Cancer · Cancer

#Cancer#Antibody#Phase3#monoclonal-antibody#HeadandNeckNeoplasms+3
Trials 31Status Recruiting
ADCLimited DatastaleCSPC ZhongQi Pharmaceutical Tec…Phase 1

an antibody drug conjugate (an antibody drug conjugate)

Neoplasms · Neoplasms

#Neoplasms#ADC#Phase1#antibody-drug-conjugate#CSPC
Trials 31Status Active
AntibodyLimited DatastaleQuantumLeap Healthcare Collabor…Phase 2

AMG 479 (AMG 479, Ganitumab, AMG 479 (Ganitumab) plus Metformin)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#BreastNeoplasms+3
Trials 30Status Recruiting
ADCStandard DatabasestaleRochePhase 2

ado-trastuzumab emtansine (Kadcyla, T-DM1, T-DM1 and Pertuzumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastNeoplasms+2
Trials 30Status Recruiting
ADCCurated CorestaleMerck Sharp & Dohme LLCPhase 3

Patritumab Deruxtecan (Patritumab Deruxtecan)

Breast Neoplasms; Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase3#BioJungboMoa-pick#antibody-drug-conjugate+3
Trials 29Status Recruiting
ADCStandard DatabasestaleGileadPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Sacituzumab Govitecan / Trastuzumab Deruxtecan)

Triple Negative Breast Neoplasms; Neoplasm Metastasis · Triple Negative Breast Neoplasms

#TripleNegativeBreastNeoplasms#ADC#Phase2#antibody-drug-conjugate#NeoplasmMetastasis+1
Trials 24Status Recruiting
AntibodyLimited DatastaleRegeneronPhase 2

Cemiplimab plus REGN3767 (Cemiplimab plus REGN3767)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#BreastNeoplasms+2
Trials 23Status Recruiting
AntibodyLimited DatastalePfizerPhase 1

sasanlimab (sasanlimab)

Carcinoma, Pancreatic Ductal; Colorectal Neoplasms · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase1#monoclonal-antibody#Carcinoma+3
Trials 23Status Discontinued

1 / 5 pages

← PreviousNext →